HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tanja Fehm Selected Research

Lymphatic Metastasis

9/2010Small cell carcinoma of vulva: curative multimodal treatment in face of resistance to initial standard chemotherapy.
9/2005Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor.
8/2005A pooled analysis of bone marrow micrometastasis in breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tanja Fehm Research Topics

Disease

153Breast Neoplasms (Breast Cancer)
06/2022 - 09/2002
117Neoplasms (Cancer)
06/2022 - 07/2002
35Circulating Neoplastic Cells
06/2022 - 12/2004
19Neoplasm Metastasis (Metastasis)
02/2022 - 09/2002
14Ovarian Neoplasms (Ovarian Cancer)
02/2022 - 06/2004
7Carcinogenesis
01/2020 - 02/2009
6Residual Neoplasm
02/2022 - 01/2008
5Disease Progression
01/2017 - 01/2007
4Uterine Cervical Neoplasms (Cancer of the Cervix)
02/2022 - 01/2012
4Noninfiltrating Intraductal Carcinoma (DCIS)
12/2021 - 01/2015
4Carcinoma (Carcinomatosis)
07/2013 - 09/2010
3Pain (Aches)
08/2021 - 09/2017
3Inflammation (Inflammations)
02/2021 - 01/2008
3Triple Negative Breast Neoplasms
12/2020 - 01/2018
3Hemorrhage
01/2019 - 01/2012
3Prostatic Neoplasms (Prostate Cancer)
11/2018 - 01/2013
3Lymphatic Metastasis
09/2010 - 08/2005
2Arthralgia (Joint Pain)
08/2021 - 10/2019
2Vulvar Neoplasms (Vulvar Cancer)
12/2020 - 01/2016
2Hypertension (High Blood Pressure)
01/2020 - 01/2012
2Pathologic Complete Response
01/2018 - 01/2018

Drug/Important Bio-Agent (IBA)

38Hormones (Hormone)IBA
01/2022 - 08/2005
23Progesterone Receptors (Progesterone Receptor)IBA
11/2021 - 09/2005
21Biomarkers (Surrogate Marker)IBA
02/2022 - 05/2004
14Proteins (Proteins, Gene)FDA Link
04/2020 - 06/2004
11Estrogen ReceptorsIBA
12/2020 - 09/2002
11Epithelial Cell Adhesion MoleculeIBA
11/2018 - 11/2007
10Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2022 - 05/2010
9Docetaxel (Taxotere)FDA Link
10/2018 - 05/2010
8Trastuzumab (Herceptin)FDA Link
06/2022 - 06/2004
8DNA (Deoxyribonucleic Acid)IBA
06/2022 - 11/2007
8AnthracyclinesIBA
01/2022 - 05/2008
8Estrogens (Estrogen)FDA Link
01/2020 - 09/2005
7Progestins (Progestagens)IBA
11/2021 - 04/2011
7Diphosphonates (Bisphosphonates)IBA
08/2021 - 07/2012
6RNA (Ribonucleic Acid)IBA
06/2022 - 05/2006
6taxaneIBA
01/2022 - 05/2008
6Zoledronic Acid (Zometa)FDA Link
08/2021 - 07/2012
6Pharmaceutical PreparationsIBA
01/2020 - 01/2003
6Epirubicin (Ellence)FDA LinkGeneric
01/2018 - 05/2010
6PlatinumIBA
11/2016 - 11/2007
5Aromatase InhibitorsIBA
12/2020 - 09/2010
5human ERBB2 proteinIBA
12/2020 - 01/2012
5Bevacizumab (Avastin)FDA Link
01/2020 - 01/2012
5Doxorubicin (Adriamycin)FDA LinkGeneric
11/2016 - 01/2003
5Estrogen Receptor alphaIBA
01/2016 - 01/2008
5Keratins (Keratin)IBA
01/2008 - 07/2002
4Paclitaxel (Taxol)FDA LinkGeneric
06/2022 - 11/2007
4ErbB Receptors (EGF Receptor)IBA
11/2021 - 01/2007
4Phenobarbital (Luminal)FDA Link
11/2020 - 01/2015
4Carboplatin (JM8)FDA LinkGeneric
01/2020 - 11/2007
4Protein Isoforms (Isoforms)IBA
01/2020 - 01/2008
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2019 - 01/2012
4Biological ProductsIBA
11/2018 - 05/2004
4ProgesteroneFDA LinkGeneric
12/2016 - 04/2011
4Monoclonal AntibodiesIBA
07/2014 - 01/2008
4AntigensIBA
04/2014 - 11/2007
4Adenosine Triphosphate (ATP)IBA
08/2012 - 03/2008
3Capecitabine (Xeloda)FDA Link
02/2022 - 05/2010
3Norethindrone (Norethisterone)FDA LinkGeneric
11/2021 - 05/2013
3TamoxifenFDA LinkGeneric
12/2020 - 05/2006
3LigandsIBA
01/2020 - 01/2013
3Messenger RNA (mRNA)IBA
01/2020 - 01/2003
3Letrozole (Femara)FDA LinkGeneric
10/2019 - 01/2017
3pertuzumabIBA
12/2018 - 03/2013
3Fluorouracil (Carac)FDA LinkGeneric
01/2018 - 07/2012
3AntibodiesIBA
09/2015 - 03/2013
3Tumor Biomarkers (Tumor Markers)IBA
09/2015 - 05/2005
3Estradiol (Delestrogen)FDA LinkGeneric
02/2015 - 08/2011
3Indicators and Reagents (Reagents)IBA
02/2012 - 01/2009
2Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
02/2022 - 05/2021
2Vinorelbine (Navelbine)FDA LinkGeneric
11/2021 - 08/2013
2LipidsIBA
01/2021 - 01/2020
2eribulinFDA Link
04/2020 - 02/2016
2CytokinesIBA
01/2020 - 11/2018
2Carbonic Anhydrase IXIBA
01/2019 - 07/2011
2Drug CombinationsIBA
12/2018 - 06/2011
2GemcitabineFDA Link
10/2018 - 01/2016
2Circulating Tumor DNAIBA
11/2017 - 01/2016

Therapy/Procedure

80Therapeutics
06/2022 - 09/2002
48Drug Therapy (Chemotherapy)
06/2022 - 11/2007
21Neoadjuvant Therapy
06/2022 - 01/2006
10Radiotherapy
02/2022 - 09/2010
10Adjuvant Chemotherapy
08/2021 - 06/2011
3Immunotherapy
02/2022 - 11/2020
3Palliative Care (Palliative Therapy)
02/2022 - 08/2011
3Lymph Node Excision (Lymph Node Dissection)
11/2021 - 09/2005
3Chemoradiotherapy
04/2020 - 09/2010
3Mastectomy (Mammectomy)
04/2020 - 12/2004
3Lasers (Laser)
09/2018 - 05/2006
2Combination Drug Therapy (Combination Chemotherapy)
06/2022 - 11/2016
2Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
02/2022 - 02/2022
2Brachytherapy
02/2022 - 02/2022
2Hormone Replacement Therapy (Therapy, Hormone Replacement)
11/2021 - 09/2017
2Duration of Therapy
08/2021 - 10/2011
2Segmental Mastectomy (Lumpectomy)
04/2020 - 07/2018
2Hysterectomy
02/2019 - 07/2011
2Aftercare (After-Treatment)
11/2018 - 10/2018
2Cesarean Section (Caesarean Section)
09/2017 - 10/2007
2Complementary Therapies (Alternative Medicine)
05/2017 - 01/2017